REPARE THERAPEUTICS INC (RPTX)
US7602731025 - Common Stock
Overall RPTX gets a fundamental rating of 3 out of 10. We evaluated RPTX against 573 industry peers in the Biotechnology industry. While RPTX has a great health rating, there are worries on its profitability. RPTX is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
RPTX had negative earnings in the past year.
RPTX had a negative operating cash flow in the past year.
In the past 5 years RPTX always reported negative net income.
In the past 5 years RPTX reported 4 times negative operating cash flow.
1.2 Ratios
RPTX has a Return On Assets of -36.92%. This is in the better half of the industry: RPTX outperforms 60.92% of its industry peers.
RPTX has a better Return On Equity (-44.20%) than 70.25% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -36.92% | ||
| ROE | -44.2% | ||
| ROIC | N/A |
ROA(3y)-24.63%
ROA(5y)-23.07%
ROE(3y)-30.56%
ROE(5y)-28.11%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
RPTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
RPTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for RPTX has been increased compared to 1 year ago.
RPTX has more shares outstanding than it did 5 years ago.
RPTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
RPTX has an Altman-Z score of -0.16. This is a bad value and indicates that RPTX is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -0.16, RPTX is in the better half of the industry, outperforming 61.80% of the companies in the same industry.
There is no outstanding debt for RPTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.16 |
ROIC/WACCN/A
WACC9.94%
2.3 Liquidity
RPTX has a Current Ratio of 6.24. This indicates that RPTX is financially healthy and has no problem in meeting its short term obligations.
RPTX's Current ratio of 6.24 is fine compared to the rest of the industry. RPTX outperforms 62.50% of its industry peers.
A Quick Ratio of 6.24 indicates that RPTX has no problem at all paying its short term obligations.
With a decent Quick ratio value of 6.24, RPTX is doing good in the industry, outperforming 63.03% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.24 | ||
| Quick Ratio | 6.24 |
3. Growth
3.1 Past
RPTX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -993.33%.
RPTX shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -61.20%.
Measured over the past years, RPTX shows a very strong growth in Revenue. The Revenue has been growing by 699.65% on average per year.
EPS 1Y (TTM)-993.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-192.86%
Revenue 1Y (TTM)-61.2%
Revenue growth 3Y699.65%
Revenue growth 5YN/A
Sales Q2Q%-96.45%
3.2 Future
RPTX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.35% yearly.
RPTX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 20.56% yearly.
EPS Next Y-3.69%
EPS Next 2Y-21.88%
EPS Next 3Y-14.01%
EPS Next 5Y13.35%
Revenue Next Year-3.37%
Revenue Next 2Y-57.88%
Revenue Next 3Y-18.19%
Revenue Next 5Y20.56%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
RPTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year RPTX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
RPTX's earnings are expected to decrease with -14.01% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-21.88%
EPS Next 3Y-14.01%
5. Dividend
5.1 Amount
No dividends for RPTX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
REPARE THERAPEUTICS INC
NASDAQ:RPTX (9/19/2024, 4:06:13 PM)
3.5
+0.18 (+5.42%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap148.57M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -36.92% | ||
| ROE | -44.2% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.2
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 6.24 | ||
| Quick Ratio | 6.24 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-993.33%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y-3.69%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-61.2%
Revenue growth 3Y699.65%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y